Keep up with the latest news from Wisconsin’s innovation community with these recent headlines:
—NeuroPointDX, a business division of Madison-based Stemina Biomarker Discovery focused on diagnostics for neurological disorders, announced a partnership with New York-based Ovid Therapeutics. The collaboration is aimed at identifying novel biomarkers of Angelman syndrome, a rare genetic disorder characterized by intellectual disability, seizures, and jerky physical movements. The two companies plan to identify the new biomarkers by analyzing data related to changes in small molecules in the metabolism. Ultimately, the study could help select the patients most likely to respond to treatment, the companies said. Read the full story here.